Structure of herd immunity to SARS-COV-2 in the Krasnoyarsk region population in the COVID-19 epidemic

Purpose. Determination of the SARS-CoV-2 population humoral immunity among the population of the Krasnoyarsk Territory during the COVID-19 epidemic.

Materials and methods. The study was carried out as a part of project for assessing population immunity to SARS-CoV-2 among the population of Russian Federation using unified methodology developed by Rospotrebnadzor, with the participation of the Research Institute for Epidemiology and Microbiology named by Pasteur, and taking into account the recommendations of the WHO. The work involved 2907 volunteers, selected by the online survey and randomization by age and territory. All volunteers were divided into 7 age groups: 1–17, 18–29, 30–39, 40–49, 50–59, 60–69, 70 and older (70+), including a total 246–449 people. Population immunity testing was carried out during the formation of groups (1st stage), and then twice more, with the interval of 6–8 weeks. Serum was obtained from venous blood samples obtained from volunteers, in which antibodies to the SARS-CoV-2 nucleocapsid were determined by the enzyme immunoassay. The results were analyzed by methods of nonparametric statistics: median, interquartile range, rank correlation coefficient were calculated in the Excel statistical package. The confidence interval to seroprevalence indicators (95% CI) was calculated using the WinPepi statistical package (version 11.65). The statistical significance of the differences was assessed with a probability level of p ≤ 0.05.

Results. The seroprevalence of the population of the Krasnoyarsk Territory during the 5-month period of seromonitoring had increased 3.3 times from 12.8% (95% CI 11.3–14.4) to 41.7% (95% CI 39.4–4.0) , while the grouping by age had not revealed any peculiarities throughout the study. The trend towards a decrease in the incidence was formed on the 6th week of 2021. The seroprevalence of convalescents after COVID-19 during the initial testing was 61.5% (95% CI 40,6–79.8), among those who were in contact with patients with COVID-19 or convalescents –23.8% (95% CI 13.9–36.2) . Among the volunteers, 347 seropositive persons were identified, 324 of which were observed asymptomatic course.

Conclusion. The structure of the population humoral immunity to SARS-CoV-2 of he population of the Krasnoyarsk Territory has been investigated. It was found that an increase in seroprevalence to 41.7% (95% CI 39.4–4.0) was accompanied by a decrease in morbidity.

1. Coronavirus. Coronavirus Statistics in Russia and the World Available from: https: //coronavirus-monitor. info [Date of access: 05/10/2021]

2. Confirmed case of a new coronavirus infection COVID-2019 in Krasnoyarsk region. Available from: https://kraszdrav.ru/news/8174. [date of access: 05/10/2021]

3. To KK.-W, Sridhar S, Chiu KH-Y, Hung DL–L, Li X, Hung IF-N, et al. Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic. Emerg. Microbes Infect. 2021; 10 (1): 507–535. doi: 10.1080/22221751.2021.1898291

4. Ni L, Ye F, Cheng M–L, Feng Y, Deng Y-Q, et al. Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. Immunity. 2020; 52 (6): 971–977. e3. doi: 10.1016/j.immuni.2020.04.023

5. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva antibody responses to SARSCoV-2 spike antigens in COVID-19 patients Observational Study. Sci. Immunol. 2020; 5 (52): eabe5511. doi: 10.1126/sciimmunol.abe5511

6. Amanat, F, Stadlbauer, D, Strohmeier, S. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat. Med. 2020; 26 (7): 1033–1036. doi.org/10.1038/s41591-020-0913-5/

7. Burgess S, Ponsford MJ, Gill D. We underestimating seroprevalence of SARS-CoV-2. BMJ. 2020; 370: m3364. doi: https://doi.org/10.1136/bmj.m3364

8. Wu C, Qavi AJ, Hachim A, Kavian N, Cole1 AR, Moyle AB, et al. Characterization of SARS-CoV-2 N protein reveals multiple functional consequences of the C-terminal domain. BioRxiv. 2020: 404905. doi.org/10.1101/2020.11.30.404905

9. Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Shiadeh MN, Esfandyari S, et. al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin. Microbiol. Infect. 2021; 27 (3). doi: 10.1016/j.cmi.2020.10.020

10. Randolph HE, Barreiro LB. Herd Immunity: Understanding COVID-19. Immunity. 2020; 52 (5): 737–741. doi: 10.1016/j.immuni.2020.04.012

11. Lourenço J, Paton R, Thompson C, Klenerman P, Gupta S. Fundamental principles of epidemic spread highlight the immediate need for large-scale serological surveys to assess the stage of the SARS-CoV-2 epidemic. MedRxiv. 2029; 2004229. doi.org/10.1101/2020.03.24.2004229

12. Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol. 2020; 11: 586781. doi: 10.3389/fimmu.2020.586781

13. Popova A.Yu., Ezhlova E. B., Melnikova A. A., Bashketova N. S., Fridman R. K., Lyalina L.V. Population immunity to SARS-CoV-2 among the population of St. Petersburg during the COVID-19 epidemic. Problems of especially dangerous infections. 2020; 3: 124–130. (In Russian). doi: 10.21055/0370-1069-2020-3-124-130

14. Newcombe RG. Two-Sided Confidence Intervals for the Single Proportion: Comparison of Seven Methods. Statistics in Medicine. 1998; 17: 857–887. doi: 10.1002/(sici)1097–0258(19980430)17:8<857::aid-sim777>3.0.co;2-e

15. Popova AYu, Ezhlova EB, Melnikova AA, Historian OA, Mosevich OS, Lyalina LV, et al. Assessment of population immunity to SARS-CoV-2 among the population of the Leningrad Region during the COVID-19 epidemic. Problems of especially dangerous infections. 2020; 3: 114–123. doi: 10.21055/0370-1069-2020-3-114-123 (In Russian)

16. Standart error of fraction. Available from: https://statanaliz.info/statistica/opisaniedannyx/dispersiya-istandartnaya-oshibka-doli [Date of access: 9.05.2021]

17. Popova AYu, Andreeva EE, Babura EA, Balakhonov SV, Bashketova NS, Bulanov MV, et al. Features of the formation of seroprevalence of the population of the Russian Federation to the SARS nucleocapsid -CoV-2 in the first wave of the COVID-19 epidemic. Infection and immunity. 2021.11 (2): 297–323. doi: 10.15789/2220-7619-FOD-1684 (In Russian)

18. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Dynamics and significance of the antibody response to SARS-CoV-2 infection. MedRxiv. 2020; 20155374. doi: 10.1101/2020.07.18.20155374

19. Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2. Emerg. Infect. Dis. 2020; 26 (7): 1470–1477. doi: 10.3201/eid2607.200282

20. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). Science. 2020; 368 (6490): 489–493. doi: 10.1126/science.abb3221

21. Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, Occurrence and transmission potential of asymptomatic and pre-symptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. PLoS Med. 2020; 17 (9): e1003346. doi: 10.1371/journal.pmed.1003346

22. 22 Oran DP, Topol EJ. Prevalence of Asymptomatic SARSCoV-2 Infection. A Narrative Review. Ann. Intern. Med. 2020; 173 (5): 362–367. doi: 10.7326/M20-3012

23. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S.-m, Hayashi K. et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int. J. Infect. Dis. 2020; 94: 154–155. doi: 10.1016/j.ijid.2020.03.020

24. Popova AYu, Ezhlova EB, Melnikova AA, Patyashina MA, Sizova EP, Yuzlibaeva LR, et al. Characterization of seroprevalence to SARS-CoV-2 among the population of the Republic of Tatarstan against the background of COVID-19. Journal of Microbiology, Epidemiology and Immunobiology. 2020; 97 (6): 518–528. doi.org/10.36233/0372-9311-2020-97-6-2. (In Russian)

25. Long Q-X, Tang X-J, Shi Q-L, Li Q, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020; 26: 1200–1204 doi: 10.1038/s41591-020-0965-6

26. Mouliou DS, Gourgoulianis KI. False-positive and false-negative COVID-19 cases: respiratory prevention and management strategies, vaccination, and further perspectives. Expert Rev. Respir. Med. 2021: 1–10. doi: 10.1080/17476348.2021.1917389